Johnson & Johnson sales
This article was originally published in The Tan Sheet
Executive Summary
J&J's acquisition of Merck's stake in the European nonprescription joint venture drove 17% jump in second quarter operational growth for the firm's McNeil OTC and nutritional franchise compared with the year-ago quarter, the firm announces in a July 13 analysts call. The new McNeil Europe subsidiary will handle the launch of Zocor Heart-Pro nonprescription statin in the UK (1"The Tan Sheet" April 26, 2004, p. 6). International consumer product sales grew 14.1%, or 9%, excluding the impact of currency exchange, to $1.01 bil., compared with the second quarter of 2003. U.S. consumer sales grew 6% to $987 mil., with worldwide consumer sales totaling $2 bil., up 7.5 % excluding currency exchange...
You may also be interested in...
J&J Buyout Of Merck Stake In Europe Was In The Works “For Some Time”
Retaining rights to future Rx-to-OTC switches and a substantial one-time cash infusion were the major drivers of Merck's decision to sell its 50% stake of an OTC venture in Europe to partner Johnson & Johnson
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.